Analysis
The Deal
Intel priced an upsized public offering of common stock at $95 a share on August 10, according to CNBC and Intel's newsroom. The deal's key terms:
- Offering size -- $20 billion, upsized from a previously announced $15 billion
- Shares sold -- 210,526,315 shares, expected to close August 12
- Net proceeds -- approximately $19.7 billion after underwriting discounts
- Underwriters' option -- up to $2.25 billion of additional shares over 30 days, with JPMorgan, Goldman Sachs, Morgan Stanley and Citigroup as joint book-running managers
“Intel had already raised its 2026 capital-expenditure forecast from $18 billion to more than $20 billion last month, with its CFO signaling further increases into 2027.”
Why Intel Is Raising Equity Now
Intel intends to use the proceeds for general corporate purposes, including capital expenditures tied to expanding its chip contract-manufacturing business -- the foundry unit Intel has spent several years and tens of billions of dollars building out to compete with TSMC and Samsung for external customers' chip production. The company pointed to demand driven by AI compute investment, citing opportunities in physical AI, purpose-built silicon, advanced packaging and external wafer manufacturing. Intel had already raised its 2026 capital-expenditure forecast from $18 billion to more than $20 billion last month, with its CFO signaling further increases into 2027.
The Turnaround Context
The equity raise lands against a real Intel stock recovery: shares have more than tripled over the past year, and the company's data-center and AI business posted 59% revenue growth last quarter, evidence that investor optimism about Intel's AI positioning has real financial results behind it rather than resting purely on narrative. That recovery is what makes a $20 billion equity raise feasible at all -- selling new shares at a depressed stock price would have diluted existing holders far more painfully than doing so after a multi-year rally.
The Competitive Landscape
Intel's foundry ambitions put it in direct competition with TSMC, whose July revenue surged 45% on AI chip demand, and Samsung's foundry division, both of which have longer track records manufacturing leading-edge chips for external customers than Intel does. Nvidia and AMD, meanwhile, remain Intel's chief rivals on the design side of AI silicon rather than manufacturing -- a distinction that matters because Intel's foundry pitch depends on winning contract-manufacturing business from companies that may also be its design competitors.
Numbers in Context
A $20 billion equity raise is a substantial sum even against Intel's own scale -- the company's market capitalization has recovered meaningfully over the past year, but a raise this size still represents real dilution for existing shareholders, priced at $95 a share against whatever level the stock settles at once the deal is absorbed. The raise is roughly comparable in size to some of the largest tech-sector equity offerings of the past decade, reflecting both the scale of AI-driven capital expenditure across the industry and Intel's specific need to fund a foundry buildout most chip designers don't have to finance from scratch.
The Counterweight
Some coverage of the raise has been openly skeptical of the underlying bet: Intel is committing tens of billions of dollars to expand foundry capacity aimed substantially at external customers who, in several cases, have not yet signed binding manufacturing contracts. That's a materially different risk than TSMC's foundry expansion, which is backed by an established base of committed customers including Apple, Nvidia and AMD. If Intel's foundry customer pipeline doesn't convert to signed, high-volume contracts at a pace that matches this capital outlay, the company risks having raised $20 billion to build capacity nobody fills.
Ahead
Watch for Intel to name specific new foundry customers over the next two quarters -- that disclosure, more than the stock offering itself, will determine whether this capital raise reads in hindsight as a well-timed bet on AI-driven demand or an expensive one made ahead of demonstrated commercial proof.
